Docetaxel-induced acute myositis: a case report with review of literature
Author:
Affiliation:
1. Department of Internal Medicine, Texas Tech University Health Sciences Center, Lubbock, TX, USA
2. Division of Hematology and Medical Oncology, Texas Tech University Health Sciences Center, Lubbock, TX, USA
Publisher
Informa UK Limited
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology,Oncology
Link
https://www.tandfonline.com/doi/pdf/10.1080/1120009X.2020.1785740
Reference30 articles.
1. Phase I and pharmacologic study of paclitaxel and cisplatin with granulocyte colony-stimulating factor: neuromuscular toxicity is dose-limiting.
2. Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer.
3. Docetaxel for treatment of solid tumours: a systematic review of clinical data
4. A prospective study of docetaxel-associated pain syndrome
5. Incidence of Taxane-Induced Pain and Distress in Patients Receiving Chemotherapy for Early-Stage Breast Cancer: A Retrospective, Outcomes-Based Survey
Cited by 5 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. A 25-Year-Old Military Recruit with Isolated Myositis Following Routine Chemoprophylaxis with Intramuscular Benzathine Penicillin G;AM J CASE REP;2024
2. Docetaxel-resistant triple-negative breast cancer cell-derived exosomal lncRNA LINC00667 reduces the chemosensitivity of breast cancer cells to docetaxel <em>via</em> targeting miR-200b-3p/Bcl-2 axis;European Journal of Histochemistry;2022-10-25
3. Docetaxel-resistant triple-negative breast cancer cell-derived exosomal lncRNA LINC00667 reduces the chemosensitivity of breast cancer cells to docetaxel via targeting miR-200b-3p/Bcl-2 axis;EUR J HISTOCHEM;2022
4. Retrospective Analysis of Induction Chemotherapy plus Concurrent Chemoradiotherapy under Intensity-Modulated Radiotherapy Mode for Locally Advanced Nasopharyngeal Carcinoma;Oncology Research and Treatment;2021
5. Antineoplastics;Reactions Weekly;2020-08
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3